Vuno Inc.
Financials
Valuation Metrics
Vuno Inc.'s Market Cap is ₩704B. At end of 2025 it was ₩3129B. Ranked #1537 of 2,421 in KR market (top 63%), #904 of 1,640 on KOSDAQ (top 55%), #59 of 96 in Health Care Equipment & Services (top 61%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 70.43B KRW | KR#1,537/2,421 Sec#59/96 |
| Revenue | 30.22B KRW | KR#2,030/2,421 Sec#67/96 |
| Net Income | -11.05B KRW | KR—/2,421 Sec—/96 |
| Total Assets | 47.95B KRW | KR#2,228/2,421 Sec#76/96 |
| Net Assets | 35.69B KRW | KR#2,116/2,421 Sec#74/96 |
| Employees | 160 | KR#1,269/2,421 Sec#41/96 |
| Value | ||
| P/B | 1.97x | KR#1,931/2,421 Sec#66/96 |
| P/S | 2.33x | KR#1,887/2,421 Sec#55/96 |
| FCF Yield | -7.60% | KR—/2,421 Sec—/96 |
| Profitability | ||
| ROE | -30.96% | KR#2,192/2,421 Sec#79/96 |
| ROA | -23.04% | KR#2,270/2,421 Sec#81/96 |
| Op. Margin | -31.95% | KR#2,181/2,421 Sec#73/96 |
| Revenue Growth | -1.68% | KR#1,613/2,421 Sec#76/96 |
| Financial Health | ||
| Debt Ratio | 34.35% | KR#675/2,421 Sec#33/96 |
| Total Debt | 5.96B KRW | KR#1,759/2,421 Sec#63/96 |
| FCF | -5.35B KRW | KR#1,512/2,421 Sec#51/96 |
| Cash | 5.33B KRW | KR#1,978/2,421 Sec#67/96 |
| Current Ratio | 3.45x | KR#478/2,421 Sec#30/96 |
| Performance | ||
| 1Y Return | -77.99% | KR#2,347/2,421 Sec#92/96 |
| 1M Return | -32.48% | KR#2,364/2,421 Sec#93/96 |
| From 52W High | -82.26% | KR#2,364/2,421 Sec#92/96 |
| 1Y MDD | -84.46% | KR#2,354/2,421 Sec#93/96 |
| Trading | ||
| Volume | 387,280 shares | KR#288/2,421 Sec#9/96 |
| Trading Value | 1.88B KRW | KR#568/2,421 Sec#11/96 |
| Foreign Own. | 1.58% | KR#1,802/2,421 Sec#69/96 |
| Per Share | ||
| EPS | -789 KRW | KR—/2,421 Sec—/96 |
| BPS | 2,549 KRW | KR#1,944/2,421 Sec#61/96 |
Company Info
Vuno, an artificial intelligence medical enterprise founded in 2014, initiated its global business after launching South Korea's first AI medical device in 2018 and listing on KOSDAQ in 2021. The company uses deep learning to analyze medical data, offering diagnostic and predictive products for cardiac arrest risk, lesion detection, X-ray findings, and arrhythmia analysis. By developing its own AI engine, Vuno has reduced dependence on IT companies and is accelerating global market expansion, including securing FDA breakthrough device designation. It is headquartered in Seocho-gu, Seoul.